Related Experiment Videos
Vancomycin pharmacokinetics in infants: relationships to indices of maturation
Insights
Postconceptional age (PCA) is the best predictor of vancomycin clearance in infants. Smaller vancomycin doses may be sufficient for therapeutic concentrations in the first two months of life.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Pediatric Pharmacokinetics
Background:
- Vancomycin is crucial for treating serious Gram-positive infections in neonates.
- Understanding vancomycin pharmacokinetics in infants is essential for safe and effective dosing.
- Infant maturation significantly impacts drug disposition, necessitating age-specific dosage adjustments.
Purpose of the Study:
- To investigate the relationship between infant maturation indices and vancomycin pharmacokinetics.
- To identify key factors predicting vancomycin clearance and volume of distribution in neonates.
- To inform optimized vancomycin dosing strategies for infants during early postnatal life.
Main Methods:
- Studied 11 infants with varying gestational and postconceptional ages (PCA).
- Administered vancomycin via intravenous infusion and collected serial blood samples.
- Utilized model-independent pharmacokinetic analysis and stepwise multiple regression to analyze data.
Main Results:
- Postconceptional age (PCA) was the strongest predictor of vancomycin clearance (CL): CL = 0.0224 PCA - 0.639 (r=0.91).
- Volume of distribution (Vdss) strongly correlated with body weight: Vdss = 0.563 weight + 0.052 (r=0.93).
- Vancomycin half-life ranged from 3.5 to 9.6 hours.
Conclusions:
- Postnatal maturation, affecting body composition and renal function, influences vancomycin disposition.
- Current vancomycin dosing guidelines may be higher than necessary for infants in the first two months.
- Optimized dosing based on PCA can achieve therapeutic vancomycin serum concentrations, potentially reducing toxicity risks.
Abstract:
The relationships between steady state pharmacokinetics of vancomycin and various indices of maturation were examined in 11 infants (gestational ages, 27 to 40 weeks; postconceptional ages (PCA), 29 to 48 weeks). Vancomycin was administered as a 10-mg/kg iv infusion over 30 minutes. Serial blood samples were obtained over a dosage interval and vancomycin serum concentrations were determined by fluorescence polarization immunoassay. Model-independent pharmacokinetic data analysis yielded values for vancomycin systemic clearance (CL), volume of distribution (Vdss) and half-life ranging from 0.032 to 0.484 liter/hour, 0.44 to 2.5 liters and 3.5 to 9.6 hours respectively. Stepwise multiple regression analysis indicated that PCA was the best single variable model to predict vancomycin clearance as described, namely: CL (liters/hour) = 0.0224 PCA (weeks) - 0.639 (r = 0.91; P less than 0.0001). Other more complex models using a combination of patient variables only modestly improved the ability to explain the variability in vancomycin clearance. Vdss was strongly related to body weight (r = 0.93; P less than 0.0001) Vdss = 0.563 weight (kg) + 0.052). Our results suggest that postnatal alterations in vancomycin disposition are related to maturational changes in body composition and renal function. These data also suggest that vancomycin doses smaller than those previously recommended may be used to achieve therapeutic steady state vancomycin serum concentrations during the first 2 months of life.